Food and Drug Administration

Antiviral Drugs Advisory Committee

November 14, 2002

Slides

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Pegasys® Hoffmann-La Roche BLA 103964-0, Dr. Emanuel Petricoin, FDA (HTM) (PPT)

Pegasys® + Copegus® Combination Therapy, Hoffmann-LaRoche (HTM) (PPT)

Pegasys® Copegus®, Hoffmann-LaRoche,Indications and Usage, FDA (HTM) (PPT)

Open Public Hearing

Peginterferon a2a/Ribavirin, Dr. Brian Murphy, MD, Mph, MS, InterMune (HTM) (PPT)